Table 2 Adverse events during induction and maintenance phases
|  | Induction phase: 1–4 cycles (N = 47) | Maintenance phase: 5 cycles- (N = 41) | ||
|---|---|---|---|---|
|  | All grade | Grade ≥ 3 | All grade | Grade ≥ 3 |
Leukopenia | 46 (97.8%) | 28 (59.6%) | 4 (9.8%) | 0 |
Neutropenia | 46 (97.8%) | 45 (95.7%) | 2 (4.9%) | 0 |
Febrile neutropenia | 4 (8.5%) | 4 (8.5%) | 0 | 0 |
Anemia | 47 (100%) | 2 (4.3%) | 27 (65.9%) | 0 |
Thrombocytopenia | 27 (57.4%) | 0 | 7 (17.1%) | 0 |
Hypoalbuminemia | 43 (91.5%) | 0 | 7 (17.1%) | 0 |
AST increased | 12 (25.5%) | 0 | 7 (17.1%) | 0 |
ALT increased | 17 (36.2%) | 1 (2.1%) | 5 (12.2%) | 0 |
ALP increased | 18 (37.3%) | 0 | 8 (19.5%) | 0 |
Creatinine increased | 25 (53.2%) | 0 | 17 (41.5%) | 0 |
Anorexia | 43 (91.5%) | 6 (12.8%) | 3 (7.3%) | 0 |
Nausea | 39 (83.0%) | 6 (12.8%) | 4 (9.8%) | 0 |
Vomiting | 13 (27.7%) | 0 | 0 | 0 |
Diarrhea | 17 (36.2%) | 3 (6.4%) | 2 (4.9%) | 0 |
Constipation | 19 (40.4%) | 0 | 2 (4.9%) | 0 |
Weight loss | 27 (57.4%) | 0 | 8 (19.5%) | 0 |
Fatigue | 24 (51.1%) | 0 | 6 (14.6%) | 0 |
Alopecia | 38 (80.9%) | 0 | 19 (46.3%) | 0 |
Oral mucositis | 10 (21.3%) | 0 | 1 (2.4%) | 0 |
Sensory neuropathy | 8 (17.0%) | 0 | 10 (24.4%) | 0 |
Fever | 7 (14.9%) | 1 (2.1%) | 2 (4.9%) | 0 |
Hypertension | 44 (93.6%) | 15 (31.9%) | 34 (82.9%) | 14 (34.1%) |
Proteinuria | 32 (68.1%) | 0 | 13 (31.7%) | 0 |
Nasal bleeding | 9 (19.1%) | 0 | 5 (12.2%) | 0 |